

Table of Contents

LIST OF FIGURES	xv
LIST OF TABLES	xxi
LIST OF ABBREVIATIONS	xxiii
PREFACE.....	xxv
Chapter 1: Introduction	2
1. Introduction.....	2
1.1 Reservations with respect to conventional therapy	2
1.2 Spontaneous cancer regression	3
1.3 Quantitative systems biology formulation	5
1.4 Mechanism of complete tumour regression negative using biasing	6
1.5 Melanoma cancer: as a case study of spontaneous regression process.....	9
1.6 Melanoma signalling pathway.....	11
1.6.1 MAP Kinase-ERK dependent pathway.....	12
1.6.2 PI3Kinase-AKT dependent pathway	13
1.7 Research objective	13
1.8 Scope of the thesis	14
Chapter 2: Computational systems biology approach for Permanent tumour elimination and normal tissue protection using negative biasing.....	18
2. Outline.....	18
2.1 Introduction.....	19
2.2 Materials and methods	22
2.2.1 Formulating the computational framework of spontaneous tumour regression: 22	
2.2.2 Systems analysis of tumour extinction:.....	24
2.2.3 Equivalence between endogenous and exogenous tumour regression	26
2.2.4 Formulation of extinction of tumour cells.....	29
2.2.5 Protection of normal host tissue	34
2.2.6 Bounds of parameters in endogenous and exogenous tumour regression	34
2.2.6.1 Bounds of DNA damage.....	34
2.2.6.2 Bounds of antitumour factors	36
2.2.7 Path of complete tumour regression process	39

2.2.8	Computational modelling of Endogenous or Exogenous regression	41
2.2.9	Model corroboration by collateral experimental findings: Complete elimination of malignant cell population by first-order kinetics.....	43
2.3	Results.....	44
2.3.1	Mathematical modelling and computational simulation for tumour regression model	44
2.3.2	Tumour system behavior	44
2.3.2.1	Tumour regression under conventional therapy (without Negative Bias): Tumour Relapse	45
2.3.2.2	Tumour regression by negative bias formulation: Permanent tumour elimination	46
2.3.2.3	Behaviour of cancer stem cells, natural killer cells and circulating lymphocytes	49
2.3.2.4	Adaptability and robustness of tumour elimination process	50
2.3.2.5	General characteristics of tumour regression process	50
2.3.2.6	Basis of the tri-phasic activation.....	52
2.3.3	Model corroboration by collateral experimental findings: Complete tumour eradication by First-order kinetics	54
2.3.3.1	Exponential decline without negative bias:	57
2.3.3.2	Exponential decline with negative bias:	58
2.4	Discussion.....	60
2.4.1	Normal tissue protection	60
2.4.2	Robustness of cancer stem cell abolition with negative bias	61
2.4.3	Double pulsed lymphocyte activation for final tumour eradication.....	62
2.4.4	Therapeutic implications of the natural process of spontaneous regression of tumour	63
2.5	Conclusions	64
Chapter 3: Experimental validation of the profile of antitumour entities that enable permanent tumour elimination.....		68
3.	Outline.....	68
3.1	Introduction	69
3.2	Materials and methods	72
3.2.1.	Validation of our computational model using experimental biological system	72
3.2.2	Pre-clinical investigation	73
3.2.3	Normalization and statistical analysis.....	74
3.2.4	Time dependent biological function analysis using pathway study	74
3.3.	Results	75
3.3.1	First-order kinetics: Path for complete tumour regression	75

3.3.2 Overall profile of Permanent Tumour Remission process	77
3.3.3 Experimental validation.....	78
3.3.4. Malignant melanoma elimination	79
3.3.4.1. Melanoma microarray data preprocessing	79
3.3.4.2. Identification of signaling pathways.....	79
3.3.4.3. Identification of genes	82
3.3.5 Negative bias related genes: CASP7, GZMB	84
3.3.6 Malignant histiocytoma elimination	85
3.4. Discussion	86
3.4.1 Practical implementation: Enforcement of tumour extinction—computational feedback approach.....	88
3.4.2 Clinical translation: Towards complete tumour elimination by negative biasing 89	
3.5. Conclusions.....	90
Chapter 4: A Mechanistic Analysis of Spontaneous Cancer Remission Phenomenon Identification of Genomic Basis and Effector Biomolecules for Therapeutic Applicability: Melanoma as a case study.....	94
4. Outline	94
4.1 Introduction.....	95
4.2 Materials and Methods	98
4.2.1 Formulation of Genomic and Pharmacological Analysis	98
4.2.2 Microarray investigation of preclinical study	98
4.2.3 Identification of differentially expressed genes (DEGs) of tumour regression	99
4.2.4 Biological Signaling Pathway analysis.....	99
4.2.5 Gene Ontology and Pathway Enrichment Analysis	99
4.2.6 Protein-Protein Interaction Network Construction and Hub-Gene Identification..	100
4.2.7 Identification of Candidate Drugs from Hub Gene Interaction	100
4.2.8 Molecular Processes Study and Drug-Ligand Interaction.....	100
4.2.9 Corroboration on Human Subjects: Normal Controls and Melanoma Tumour Patients.....	101
4.3 Results	101
4.3.1 Formulation of Genomic and Pharmacological Analysis	101
4.3.2 Microarray Investigation and Analysis	101
4.3.3 IPA Signaling Pathway Analysis	103
4.3.4 Identification of Genes (DEGs) enabling first-order kinetics of tumour regression	107
4.3.5 Protein-Protein Networking analysis.....	116
4.3.6 Functional Enrichment analysis.....	120

4.3.7 Protein-Protein interaction analysis and Sub-network analysis.....	122
4.3.8 Identification of Hub Genes:	125
4.3.9. Identification of Candidate Drugs	127
4.3.10 Molecular docking for TOP2A	130
4.3.11 Corroboration from Human Subjects and Clinical Patients	134
4.4 Discussion.....	136
4.5 Conclusion.....	140
Chapter 5: Spontaneous cancer regression as reversion of spontaneous cancer progression: Molecular targets and pharmacological implications	142
5. Outline.....	142
5.1 Introduction	143
5.2 Methods and Materials:.....	146
5.2.1 Data Collection and Investigation:	146
5.2.2 Identification of differentially expressed genes (DEGs) of spontaneous melanoma regression data:	146
5.2.3 Gene Ontology Analysis:	147
5.2.4 Identification of Melanoma regression genes:	147
5.2.5 Identification of target proteins.....	148
5.2.6 Drug Identification	151
5.2.7 Validation of Drug using Molecular docking.....	151
5.2.7.1 Molecular docking with BRAF and NRAS:	151
5.2.7.2 Molecular dynamic simulation:.....	153
5.3 Result	154
5.3.1 Microarray data analysis and DEGs identification	155
5.3.2 Gene enrichment analysis of DEGs	156
5.3.3 Identification of melanoma tumour regression driving genes	158
5.3.4 Downstream signaling pathway of Melanoma and its target protein	161
5.3.5 Identification of Drugs	162
5.3.6 Molecular Docking with BRAF and NRAS	162
5.3.7 Molecular dynamics simulation investigation	167
5.4 Discussion.....	171
5.5 Conclusion.....	175
Chapter 6: Conclusion	178
6.1 Conclusion.....	178
6.2 Future scope of work	182
REFERENCES.....	185

APPENDIX-I.....	199
APPENDIX-II	209
APPENDIX – III (A).....	229
APPENDIX – III (B).....	247